Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

On Thursday, the FDA proposed removing oral phenylephrine from the list of approved active ingredients for over-the-counter ...

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...

This follows an extensive review that found the drug ineffective for treating nasal congestion. Oral phenylephrine, widely ...

A panel last year said it found evidence the ingredient, used in many popular medicines, did not aid with nasal congestion.

The debate about the effectiveness of phenylephrine as an oral decongestant has been going on for some time and science now ...

The US Food and Drug Administration announced a proposal to remove oral phenylephrine - a common ingredient in many popular ...

Last September, an FDA advisory panel determined that phenylephrine was not effective when taken in oral form. It is also ...

Only a final order will affect what products can be marketed. Among the products containing oral phenylephrine as an active ingredient are Sudafed PE, Vicks Nyquil Sinex Nighttime Sinus Relief and ...

Share on Facebook Share on Twitter The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the ...

by AstraZeneca and Amgen has shown significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), ...